PMID- 38266702 OWN - NLM STAT- MEDLINE DCOM- 20240325 LR - 20240325 IS - 1873-5118 (Electronic) IS - 0301-0082 (Linking) VI - 234 DP - 2024 Mar TI - Digging into the intrinsic capacity concept: Can it be applied to Alzheimer's disease? PG - 102574 LID - S0301-0082(24)00010-8 [pii] LID - 10.1016/j.pneurobio.2024.102574 [doi] AB - Historically, aging research has largely centered on disease pathology rather than promoting healthy aging. The World Health Organization's (WHO) policy framework (2015-2030) underscores the significance of fostering the contributions of older individuals to their families, communities, and economies. The WHO has introduced the concept of intrinsic capacity (IC) as a key metric for healthy aging, encompassing five primary domains: locomotion, vitality, sensory, cognitive, and psychological. Past AD research, constrained by methodological limitations, has focused on single outcome measures, sidelining the complexity of the disease. Our current scientific milieu, however, is primed to adopt the IC concept. This is due to three critical considerations: (I) the decline in IC is linked to neurocognitive disorders, including AD, (II) cognition, a key component of IC, is deeply affected in AD, and (III) the cognitive decline associated with AD involves multiple factors and pathophysiological pathways. Our study explores the application of the IC concept to AD patients, offering a comprehensive model that could revolutionize the disease's diagnosis and prognosis. There is a dearth of information on the biological characteristics of IC, which are a result of complex interactions within biological systems. Employing a systems biology approach, integrating omics technologies, could aid in unraveling these interactions and understanding IC from a holistic viewpoint. This comprehensive analysis of IC could be leveraged in clinical settings, equipping healthcare providers to assess AD patients' health status more effectively and devise personalized therapeutic interventions in accordance with the precision medicine paradigm. We aimed to determine whether the IC concept could be extended from older individuals to patients with AD, thereby presenting a model that could significantly enhance the diagnosis and prognosis of this disease. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved. FAU - Lopez-Ortiz, Susana AU - Lopez-Ortiz S AD - i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain. FAU - Caruso, Giuseppe AU - Caruso G AD - Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy; Neuropharmacology and Translational Neurosciences Research Unit, Oasi Research Institute-IRCCS, 94018 Troina, Italy. FAU - Emanuele, Enzo AU - Emanuele E AD - 2E Science, 27038 Robbio 27100, Pavia, Italy. FAU - Menendez, Hector AU - Menendez H AD - i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain. FAU - Penin-Grandes, Saul AU - Penin-Grandes S AD - i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain. FAU - Guerrera, Claudia Savia AU - Guerrera CS AD - Department of Educational Sciences, University of Catania, 95125 Catania, Italy; Department of Biomedical and Biotechnological Sciences, University of Catania, 95125 Catania, Italy. FAU - Caraci, Filippo AU - Caraci F AD - Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy; Neuropharmacology and Translational Neurosciences Research Unit, Oasi Research Institute-IRCCS, 94018 Troina, Italy. FAU - Nistico, Robert AU - Nistico R AD - School of Pharmacy, University of Rome "Tor Vergata", 00133 Rome, Italy; Laboratory of Pharmacology of Synaptic Plasticity, EBRI Rita Levi-Montalcini Foundation, 00143 Rome, Italy. FAU - Lucia, Alejandro AU - Lucia A AD - Research Institute of the Hospital 12 de Octubre ('imas12'), 28041 Madrid, Spain; Faculty of Sport Sciences, European University of Madrid, 28670 Villaviciosa de Odon, Madrid, Spain; CIBER of Frailty and Healthy Ageing (CIBERFES), 28029 Madrid, Spain. FAU - Santos-Lozano, Alejandro AU - Santos-Lozano A AD - i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain; Research Institute of the Hospital 12 de Octubre ('imas12'), 28041 Madrid, Spain. FAU - Lista, Simone AU - Lista S AD - i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain. Electronic address: slista@uemc.es. LA - eng PT - Journal Article DEP - 20240122 PL - England TA - Prog Neurobiol JT - Progress in neurobiology JID - 0370121 SB - IM MH - Humans MH - *Alzheimer Disease MH - *Cognitive Dysfunction/diagnosis MH - Aging OTO - NOTNLM OT - Alzheimer's disease OT - Digital biomarkers OT - Digital healthcare OT - Dimensions OT - Intrinsic capacity OT - Systems biology COIS- Declaration of Competing Interest EE is the unique owner of 2E Science, a for-profit private scientific company. Neither EE nor 2E Science have any commercial interest or financial tie in relation with this article. SL-O, GC, HM, SP-G, CSG, FC, RN, AL, AS-L, and SL declare that they have no conflict of interest. EDAT- 2024/01/25 00:42 MHDA- 2024/03/25 06:42 CRDT- 2024/01/24 19:13 PHST- 2023/06/06 00:00 [received] PHST- 2024/01/09 00:00 [revised] PHST- 2024/01/18 00:00 [accepted] PHST- 2024/03/25 06:42 [medline] PHST- 2024/01/25 00:42 [pubmed] PHST- 2024/01/24 19:13 [entrez] AID - S0301-0082(24)00010-8 [pii] AID - 10.1016/j.pneurobio.2024.102574 [doi] PST - ppublish SO - Prog Neurobiol. 2024 Mar;234:102574. doi: 10.1016/j.pneurobio.2024.102574. Epub 2024 Jan 22.